High level of IL-6 is a biomarker in lung cancer patients, Cao et al. revealed that mutant EGFR could upregulate IL-6 via gp130/JAK signaling pathway targeting signal transducer and activator of transcription (STAT) 3, a known oncogenic protein (35). Here, EGFR is linked to lung carcinoma.